echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical World News > Weigh! 2019 national medical insurance negotiation successful drug list officially released (with catalog)

    Weigh! 2019 national medical insurance negotiation successful drug list officially released (with catalog)

    • Last Update: 2019-11-28
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Author: The long list of health care negotiations has finally come out Today (November 28), the National Health Insurance Bureau officially released the 2019 medical insurance negotiation access list There are 97 varieties that have entered the medical insurance catalogue through negotiation, including PD-1, xiumeile and other drugs that are widely concerned by the industry The average price reduction of 70 new drugs is 60.7%, and that of 27 renewal drugs is 26.4% So far, in 2019, the complete version of the national directory of drugs for basic medical insurance, work injury insurance and maternity insurance was published, with a total of 2709 drugs included in the directory Compared with 2017 edition, 218 drugs were transferred in, 154 drugs were transferred out, a net increase of 64 The new catalogue will be put into effect on January 1 There are 150 varieties involved in this negotiation Access Catalogue, with more than 70 enterprises participating According to the on-site media reports, most of the drugs successfully negotiated in this negotiation are newly marketed drugs with high clinical value in recent years, involving more than 10 clinical treatment fields such as cancer, rare diseases, hepatitis, diabetes, MDR-TB, rheumatism immunity, cardio cerebrovascular, digestion, etc In terms of key areas, all five essential drugs were successfully negotiated, 22 anticancer drugs, 7 drugs for rare diseases, 14 drugs for chronic diseases (including diabetes, hepatitis B, rheumatoid arthritis, etc.) and 4 drugs for children were successfully negotiated From the perspective of innovation, most of the drugs successfully negotiated in this negotiation are new drugs launched in recent years, many of which are newly launched in 2018 Eight of the 12 major domestic innovative drugs have been negotiated The first batch of medical insurance negotiations can be reviewed back to 2016, organized by the original health and Family Planning Commission There are three varieties of drugs finally negotiated for admission, including GSK tenofovir dipivoxil (Werder), beta drug, a non-small cell lung cancer targeted drug, exetane (Kemena) and AstraZeneca gefitinib (eresa) The price reductions of the three drugs are 67% and 54% respectively 55% In April 2017, the Ministry of human resources and social security released a list of 44 drugs to be negotiated After negotiations with relevant enterprises, 36 drugs in the final list were successfully negotiated in July, with a success rate of 81.8% Compared with the average retail price in 2016, the average decline of negotiated drugs reached 44%, and the highest reached 70% In June 2018, the National Health Insurance Bureau, the Ministry of human resources and social security, the national health and Health Commission, the Ministry of Finance and other departments launched special negotiations on the access of anti-cancer drugs to medical insurance outside the catalog After negotiation with enterprises, 17 kinds of anticancer drugs were included in the negotiation scope of medical insurance access Compared with the average retail price, the payment standard of negotiated drugs decreased by 56.7% on average According to the results of previous health care negotiations, we can see that the decline of drugs is less than half, and more than 70% The average price reduction of 70 new drugs in this health care negotiation is 60.7%, which is also in the range of decline in previous health care negotiations In August this year, when the health insurance bureau interpreted the new version of the health insurance catalog, it mentioned that a dynamic adjustment mechanism of the health insurance catalog was being established and relevant policy documents were being formulated In line with this trend, health care negotiations may continue in the future The large-scale effect of medical insurance on products is very obvious Only taking the "three swordsmen" Herceptin (trastuzumab for injection), rituximab (rituximab for injection) and Avastin (bevacizumab) as examples, the three anti-tumor monoclonal antibodies all entered the medical insurance with a reduction of more than 50%, especially Herceptin's reduction of 65.7% In less than half a year after entering the medical insurance, according to the PDB data of Shanghai Institute of medical technology, the sales volume of Herceptin in the sample hospital in the first quarter of 2018 increased by 164.1% compared with the same period last year, and the sales volume also reached 215 million yuan higher than the same period last year In the first quarter, the sales volume exceeded that of the same period, especially that of Avastin, whose price cut was 61.58%, with a year-on-year growth of 266% The reason why the adjustment of the medical insurance catalogue is so important is that "this is the only way" for enterprises to reduce their prices into the medical insurance catalogue When announcing the new version of the medical insurance catalogue this year, the State Medical Insurance Bureau mentioned that all localities should strictly implement the drug catalogue, and should not make their own catalogues or add drugs in the catalogue by flexible methods, or adjust the limited payment scope of drugs in the catalogue 。 In addition, the class B drugs added according to the regulations in the original provincial drug catalogue should be gradually digested within 3 years In the process of digestion, provinces should give priority to adjusting the payment scope of drugs included in the national key monitoring scope This means that for varieties that do not enter the national health insurance catalog, the access to the catalog through local supplement authority has been blocked Class B drugs added to the medical insurance at the original provincial level will be gradually transferred out within three years, and the drugs included in the national key monitoring are the priority objects Looking at the varieties that have successfully entered the medical insurance negotiation, it is obvious that after years of medical insurance negotiation, the official has formed a way of its own development for the negotiation itself, that is, according to the relevant spirit of the Central Committee, to give priority to the introduction of some drugs that are urgently needed clinically into the medical insurance For example, Premier Li Keqiang once pointed out at the executive meeting of the State Council that it is necessary to increase the number of anti-cancer drugs The strength of entering the medical insurance catalog should meet the needs of patients as soon as possible This spirit is also reflected in the negotiation results of the medical insurance catalogue The entry of xindili mAb, a kind of Xinda biological PD-1, into the medical insurance catalogue shows the official support for some new technologies and new therapies Therefore, the problem facing enterprises now is that with the continuous promotion of relevant national policies, what enterprises need to see is that innovative drugs in the pharmaceutical industry and clinical high prices In the future, it will be the direction that the government encourages research and development Of course, for enterprises, the entry of varieties still needs to be settled In this negotiation, the exit negotiation of BMS PD-1 variety o drug is also a typical negotiation, which is not in line with the enterprise's own pricing strategy and chooses to exit This involves a process of game between enterprises and the state health Insurance Bureau For the health insurance bureau, it wants to reduce the health insurance fund through this negotiation The pressure to use limited money on the blade But the enterprise itself has its own profit pressure How to balance the market and price effectively will test its own strength and strategy (click to see the big picture)
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.